Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

Reem Karmali, MD
Published: Wednesday, Oct 18, 2017



Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.


Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x